Page 2 Serial No. 10/749,914 Response to Official Action

In the Claims

- 1. (currently amended) A carrier composition for transdermal delivery of a macromolecule, comprising a <u>polyenylphosphatidylcholine-enriched</u> phosphatidylcholine component entrapping said macromolecule <u>for transdermal delivery to dermal vasculature</u>, wherein said <u>phosphatidylcholine</u> component stabilizes said macromolecule at room temperature.
- 2. (currently amended) The composition of claim 1, wherein said phosphatidylcholine component <u>further</u> comprises polenylphosphatidylcholine and at least one polyglycol.
- 3. (currently amended) The composition of claim 21, wherein said phosphatidylcholine component is polyenylphosphatidylcholine-enriched pure phosphatidylcholine.
- 4. (currently amended) The composition of claim 2, wherein said <u>at least one</u> polyglycol is polyglycol <u>E200</u> <u>having molecular weight of 200</u> and polyglycol <u>E400</u> <u>having molecular weight of 400</u>.
- 5. (currently amended) The composition of claim 2, wherein said phosphatidylcholine component comprises 45% w/w polyenylphosphatidylcholine-enriched phosphatidylcholine, 50% w/w polyglycol £200 having molecular weight of 200, and 5% w/w £400 having molecular weight of 400.
- 6. (original) The composition of claim 2, further comprising a surfactant, a lubricant, and methyl paraben.

Page 3

∢'

Serial No. 10/749,914

Response to Official Action

7. (original) The composition of claim 6, comprising 97.25% w/w phosphatidylcholine component, 1.00% w/w surfactant, 1.00% w/w lubricant, and 0.75% w/w methyl paraben.

- 8. (currently amended) The composition of claim 6, wherein said carrier further comprisesing water.
- 9. (currently amended) The composition of claim 8, wherein said carrier comprisesing 53.25% w/w polyenylphosphatidylcholine-enriched phosphatidylcholine component, 1.00% w/w surfactant, 1.00% w/w lubricant, 0.75% w/w methyl paraben and 45 44% w/w water.
- 10. (original) The composition of claim 6, wherein said surfactant is a siloxylated polyether.
- 11. (original) The composition of claim 10, wherein said siloxylated polyether is dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane.
- 12. (original) The composition of claim 6, wherein said lubricant is silicone fluid.
- 13. (original) The composition of claim 12, wherein said silicone fluid contains low viscosity polydimethylsiloxane polymers.
- 14. (original) The composition of claim 1, wherein said macromolecule is selected from the group consisting of oxytocin, vasopressin, insulin, somatotropin, calcitonin, chorionic gonadotropin, menotropins, follitropins, somatostatins, progestins, peptides, polymers, and combinations of any of these.

Page 4 Serial No. 10/749,914 Response to Official Action

15. (currently amended) A stable topical insulin composition, comprising: carrier having a <u>polyenylphosphatidylcholine-enriched</u> phosphatidylcholine component, and

insulin entrapped within said carrier <u>for transdermal delivery of the insulin to</u> <u>dermal vasculature</u>.

- 16. (currently amended) The composition of claim 15, wherein said phosphatidylcholine component <u>further</u> comprises polyenylphosphatidylcholine and at least one polyglycol.
- 17. (currently amended) The composition of claim 16, wherein said polyglycol is polyglycol E200 having molecular weight of 200 and polyglycol E400 having molecular weight of 400.
- 18. (currently amended) The composition of claim 17, wherein said phosphatidylcholine component comprises 45% w/w polyenylphosphatidylcholine-enriched polyenylphosphatidylcholine, 50% w/w polyglycol E200 having molecular weight of 200, and 5% w/w polyglycol E400 having molecular weight of 400.
- 19. (original) The composition of claim 15, wherein said carrier comprises a surfactant, a lubricant, and methyl paraben.
- 20. (original) The composition of claim 19, wherein said carrier comprises 97.25% w/w phosphatidylcholine component, 1.00% w/w surfactant, 1.00% w/w lubricant, and 0.75% w/w methyl paraben.
- 21. (original) The composition of claim 15, wherein said carrier further comprises water.

Page 5 Serial No. 10/749,914 Response to Official Action

- 22. (currently amended) The composition of claim 16, wherein said carrier comprises 53.25% w/w phosphatidylcholine component, 1.00% w/w surfactant, 1.00% w/w lubricant, 0.75% w/w methyl paraben and [[45]]44% w/w water.
- 23. (original) The composition of claim 19, wherein said surfactant is a siloxylated polyether.
- 24. (original) The composition of claim 23, wherein said wherein said siloxylated polyether is dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane.
- 25. (original) The composition of claim 23, wherein said lubricant is silicone fluid.
- 26. (original) The composition of claim 25, wherein said silicone fluid contains low viscosity polydimethylsiloxane polymers.
- 27. (cancelled)
- 28. (cancelled)
- 29. (cancelled)
- 30. (cancelled)
- 31. (cancelled)
- 32. (cancelled)
- 33. (cancelled)

Page 6 Serial No. 10/749,914 Response to Official Action

- 34. (cancelled)35. (cancelled)36. (cancelled)37. (cancelled)38. (cancelled)
- 39. (cancelled)
- 40. (new) The composition of claim 15, wherein said phosphatidylcholine component is pure polyenylphosphatidylcholine.